As students struggle with paying attention and managing stress, demand is soaring for a new—and often pricy—kind of support.
The European Medicines Agency has approved Dupixent (dupilumab) to treat eosinophilic esophagitis (EoE) in children as young as one year of age. Specifically, the approval covers children aged one to ...
Results from the trial were published in The New England Journal of Medicine.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback